Lexeo Reports Sustained Neurological Benefit for LX2006 Through 36 Months
Lexeo says its LX2006 trial showed sustained neurological benefit in Friedreich ataxia through 36 months.
Story updates
12:09:52 PM UTC
SquawkNews
Lexeo said phase I/II interim data showed sustained or deepening improvements in cardiac and neurologic measures, including statistically significant mean mFARS improvement versus a propensity-matched natural-history control. Further data will be presented at ICAR in November.Material DetailsContex…